Your browser doesn't support javascript.
loading
Prognostic impact of bone metastases detected by 18F-DOPA PET in patients with metastatic midgut neuroendocrine tumors.
Deleval, Nicolas; Pesque, Louise; Dieudonné, Arnaud; Viry, Flore; Hentic, Olivia; Lebtahi, Rachida; Ruszniewski, Philippe; de Mestier, Louis.
Afiliação
  • Deleval N; Department of Nuclear Medicine, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France.
  • Pesque L; Université de Paris, Paris, France.
  • Dieudonné A; Department of Nuclear Medicine, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France.
  • Viry F; Université de Paris, Paris, France.
  • Hentic O; Department of Nuclear Medicine, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France.
  • Lebtahi R; Department of Radiology, Lariboisière Hospital (APHP), Paris, France.
  • Ruszniewski P; Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon Hospital (APHP), 100 boulevard du Général Leclerc, 92110, Clichy, France.
  • de Mestier L; Department of Nuclear Medicine, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France.
Eur Radiol ; 31(6): 4166-4174, 2021 Jun.
Article em En | MEDLINE | ID: mdl-33247341
OBJECTIVES: Bone metastases (BM) may influence negatively the prognosis of midgut neuroendocrine tumors (NET). The diagnostic sensitivity of 18F-DOPA PET for midgut NET and associated metastases is high. This study aimed to assess the prognostic impact of BM detected by 18F-DOPA PET in metastatic midgut NET. METHODS: All patients with a metastatic midgut NET, who underwent a 18F-DOPA PET between June 2011 and June 2018, were included. BM were defined following imaging criteria and were classified as poly-BM or oligo-BM, according to their number (< 5 or ≥ 5, respectively). The variables associated with the presence of BM were evaluated by logistic regression. The factors associated with overall survival were explored by Cox regression models. RESULTS: Among 155 patients included, 46 had BM (29.7%). A carcinoid syndrome (OR 2.96, p = 0.009) and ≥ 3 extra-skeletal metastatic organs (OR 4.99, p = 0.002) were independently associated with the presence of BM. BM were mainly osteoblastic (78%), rarely symptomatic (8.9%), and had a short-term therapeutic impact for 3 patients (6.5%). The presence of BM (HR 2.67, p = 0.034), older age (HR 1.07, p = 0.016), and higher Ki67 (HR 1.09, p = 0.025) were independent prognostic factors. Unlike poly-BM (HR 1.92, p = 0.007), oligo-BM was not a poor prognosis factor (HR 0.77, p = 0.699) compared to the group without BM. CONCLUSION: 18F-DOPA PET frequently detects BM in patients with metastatic midgut NET. BM have a negative prognostic impact, especially poly-BM. Conversely, oligo-BM do not influence the prognosis and may not impact therapeutic decisions. KEY POINTS: • 18F-DOPA PET detected bone metastases in 46 (29.7%) of 155 patients with metastatic midgut neuroendocrine tumors. • Bone metastases have a negative prognostic impact in metastatic midgut neuroendocrine tumors. • Bone oligo-metastases (< 5) do not influence the prognosis and may not impact therapeutic decisions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Di-Hidroxifenilalanina / Tumores Neuroendócrinos Tipo de estudo: Prognostic_studies Limite: Aged / Humans Idioma: En Revista: Eur Radiol Assunto da revista: RADIOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Di-Hidroxifenilalanina / Tumores Neuroendócrinos Tipo de estudo: Prognostic_studies Limite: Aged / Humans Idioma: En Revista: Eur Radiol Assunto da revista: RADIOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França